deltatrials
Completed PHASE3 NCT00249795

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)

A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation

Sponsor: Bristol-Myers Squibb

Conditions Atrial Fibrillation Cardiovascular Disease
Interventions Irbesartan placebo
Updated 8 times since 2017 Last updated: Sep 29, 2010 Started: Jun 30, 2003 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

This PHASE3 trial investigates Atrial Fibrillation and Cardiovascular Disease and is currently completed. Bristol-Myers Squibb leads this study, which shows 8 recorded versions since 2003 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Change History

8 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece, Barcelona, Spain, Berlin, Germany, Bridgewater, United States, Bromma, Sweden, Budapest, Hungary, Buenos Aires, Argentina, Causeway Bay, Hong Kong, Diegem, Belgium, Geneva, Switzerland and 20 more location s